India is poised to become a major hub for producing the Sputnik V vaccine with five Indian companies having signed agreements for the production of the vaccine. The total capacity works out to around 950 million doses a year. It would be the third COVID-19 vaccine approved in India, after AsztraZeneca’s Covishield being produced at the Pune-based Serum Institute of India, and Hyderabad-based Bharat Biotech’s home-grown Covaxin developed in partnership with the Indian Council of Medical Research.
